What results do semaglutide tablets actually produce?

Step 1: The escalation phase, and why early results are modest by design

Wegovy tablets follow a structured dose-escalation schedule. Treatment opens at 1.5mg daily, progresses through 4mg and 9mg, and reaches the 25mg maintenance dose, with at least one month at each level before moving up. That pace is deliberate. Oral semaglutide is absorbed differently from the injection, and the gradual climb gives your digestive system time to settle while absorption is established.

Most people notice little significant weight change during the first few weeks. That is not a sign that the medicine isn't working; it reflects the biology of the escalation. The appetite-regulating effects of semaglutide, which acts on GLP-1 receptors involved in hunger signalling and gastric emptying, accumulate as the dose rises. Expecting dramatic early results sets the wrong benchmark. A question our prescribers hear often is "why haven't I lost more in the first month?", and the honest answer is that the first month's job is adjustment, not transformation.

The OASIS 4 trial ran for 64 weeks, and the weight-loss curve continued to slope downward well past the halfway point for many participants. Patience through escalation pays off in the maintenance phase.

Step 2: What the 13.6% average means for a real person, and the adherence detail

The headline figure from the MHRA's announcement of the Wegovy tablet approval is 13.6% average weight loss across all participants at 64 weeks. For someone starting at 100kg, that is roughly 13–14kg. For someone at 120kg, it is closer to 16–17kg.

The ~17% figure that appears elsewhere refers specifically to participants who stayed fully adherent throughout the study, every dose, every morning, on an empty stomach with a small amount of plain water, waiting at least 30 minutes before eating, drinking coffee, or taking other oral medicines. That protocol matters more for oral semaglutide than for the injection, because absorption through the gut wall is sensitive to what surrounds it at the time of dosing. Missing that 30-minute window is not a minor slip, over weeks it compounds into meaningfully lower drug exposure.

So the two figures tell a consistent story: the medicine works, and consistency amplifies that. This is worth reading alongside how long oral semaglutide takes to produce noticeable changes, where the week-by-week picture is mapped in more detail.

Step 3: Comparing the tablet's results to what the injection produces

The Wegovy injection at 2.4mg produced around 15% average weight loss over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. The tablet's 13.6% average over a slightly shorter trial is in the same region, though direct head-to-head data between the tablet and injection are not yet available, the trials differed in population, duration and design, so the comparison is indicative rather than definitive.

For context, the injectable tirzepatide (Mounjaro) produced greater average weight loss than semaglutide 2.4mg in the SURMOUNT-5 head-to-head trial. The tablet sits broadly within the semaglutide range. What it offers that the injection does not is the absence of needles and the straightforward room-temperature storage, meaningful practical advantages for some people. If you're weighing up the options, the full overview of how Wegovy tablets work covers the mechanism and the licensed indications in detail.

Thinking about what treatment costs alongside these results is reasonable. The cost of Wegovy tablets through a private UK pharmacy gives a clear picture of what to expect, including what a legitimate price should cover.

What affects whether you personally see strong results

Trial averages mask a wide spread. Some participants in OASIS 4 lost considerably more than 13.6%; others lost less. The factors that correlate with stronger results include: adherence to the dosing protocol (the 30-minute morning window), sustained dietary changes alongside treatment, and reaching the maintenance dose without interruption. Stopping and restarting causes weight to return, which is consistent with how semaglutide works, it manages appetite while you take it, rather than permanently resetting metabolism.

The prescriber's role here is not just to issue the prescription. At every repeat, a clinical review considers whether you are responding as expected, whether the escalation has gone smoothly, and whether anything has changed in your health picture. That ongoing oversight is a practical safeguard, and it's part of why understanding how long oral semaglutide stays active in your system is relevant if you ever miss a dose or consider pausing treatment. Decisions like that are for your prescriber, not the Patient Information Leaflet alone.

These are prescription-only medicines, and suitability is a clinical assessment, not a self-check. Our clinical team reviews every consultation personally before treatment is approved. If you'd like to explore whether oral semaglutide is right for you, start your free consultation here.